# Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections

> **NCT00929643** · — · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer** · enrollment: 203 (actual)

## Conditions studied

- Complicated Intra-Abdominal Infection

## Interventions

- **OTHER:** no intervention

## Key facts

- **NCT ID:** NCT00929643
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-12
- **Final completion:** 2010-12
- **Target enrollment:** 203 (ACTUAL)
- **Last updated:** 2012-08-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00929643

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00929643, "Impact Of Bacterial Resistance On Healthcare Costs For Hospitalized Patients With Complicated Intra-Abdominal Infections". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00929643. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*